It's time to phase in RHD genotyping for patients with a serologic weak D phenotype

Transfusion

Volumn 55, Issue 3, 2015, Pages 680-689

  Sandler, S Gerald ^a   Flegel, Willy A ^b   Westhoff, Connie M ^c   Denomme, Gregory A ^d   Delaney, Meghan ^e,i   Keller, Margaret A ^f   Johnson, Susan T ^d   Katz, Louis ^g   Queenan, John T ^a   Vassallo, Ralph R ^f   Simon, Clayton D ^h  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NEW YORK BLOOD CENTER   (United States)

^d BLOOD RESEARCH INSTITUTE   (United States)

^e Puget Blood Center   (United States)

^f AMERICAN RED CROSS   (United States)

^g Americas Blood Centers   (United States)

^h Armed Services Blood Program Office   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY; ALLOANTIBODY; BLOOD GROUP RHESUS SYSTEM; EPITOPE; MONOCLONAL ANTIBODY; RHO(D) ANTIBODY; RHO(D) ANTIGEN;

ALLOIMMUNIZATION; BLOOD GROUP TYPING; BLOOD TRANSFUSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE; GENOTYPING TECHNIQUE; HEMATOLOGIC DISEASE; HUMAN; NOTE; PHENOTYPE; POLICY; PREGNANT WOMAN; RECIPIENT; SEROLOGIC WEAK D PHENOTYPE; ADVERSE EFFECTS; AMINO ACID SUBSTITUTION; ANTIGEN ANTIBODY REACTION; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUP RHESUS SYSTEM; ERYTHROBLASTOSIS, FETAL; FEMALE; GENE DELETION; GENETICS; GENOTYPE; HEMAGGLUTINATION TEST; IMMUNOLOGY; LABORATORY DIAGNOSIS; MALE; NEWBORN; PRACTICE GUIDELINE; PREGNANCY; STANDARDS; TRANSFUSION REACTION;

AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; BLOOD GROUP INCOMPATIBILITY; BLOOD GROUPING AND CROSSMATCHING; BLOOD TRANSFUSION; EPITOPES; ERYTHROBLASTOSIS, FETAL; FALSE NEGATIVE REACTIONS; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEMAGGLUTINATION TESTS; HUMANS; INFANT, NEWBORN; ISOANTIBODIES; MALE; PHENOTYPE; PREGNANCY; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN; SEQUENCE DELETION; TRANSFUSION REACTION;

EID: 84924574347     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12941     Document Type: Note

References (149)

1. Sandler SG, Roseff S, Dormen RE, et-al. Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin/Results and recommendations related to supplemental questions in the comprehensive transfusion medicine survey of the College of American Pathologists. Arch Pathol Lab Med 2014; 138: 620-625.
2. Bowman J,. Thirty-five years of Rh prophylaxis. Transfusion 2003; 43: 1661-1666.
3. u). Proc Natl Acad Sci U S A 1955; 41: 283-288.
4. Stratton F,. A new Rh allelomorph. Nature 1946; 158: 25-26.
5. Mourant AE, Kopec AC, Domaniewska-Sobczak K,. The distribution of the human blood groups and other polymorphisms. 2 ed. London: Oxford University Press; 1976.
6. Salmon C, Cartron JP, Rouger P,. The human blood groups. New York: Masson; 1984.
7. Agre PC, Davies DM, Issitt PD, et-al. A proposal to standardize terminology for weak D antigen. Transfusion 1992; 32: 86-87.
8. Wagner FF, Kasulke D, Kerowgan M, et-al. Frequencies of the blood groups ABO, Rhesus, D category VI, Kell, and of clinically relevant high-frequency antigens in South-Western Germany. Infusionsther Transfusionsmed 1995; 22: 285-290.
9. N phenotypes. Blood 1996; 87: 4853-4861.
10. Huang CH,. Molecular insights into the Rh protein family and associated antigens. Curr Opin Hematol 1997; 4: 94-103.
11. Beckers EA, Faas BH, Ligthart P, et-al. Lower antigen site density and weak D immunogenicity cannot be explained by structural genomic abnormalities or regulatory defects of the RHD gene. Transfusion 1997; 37: 616-623.
12. Sandler SG, Gottschall JL,. Postpartum Rh immunoprophylaxis. Obstet Gynecol 2012; 120: 1428-1438.
13. Argall CI, Ball JM, Trentelman E,. Presence of anti-D antibody in the serum of a DU patient. J Lab Clin Med 1953; 41: 895-898.
14. Weiner AS, Geiger J, Gordon EB,. Mosaic nature of the Rho blood factor of human blood. Exp Med Surg 1957; 15: 75-82.
15. White CA, Stedman CM, Frank S,. Anti-D antibodies in D- and Du-positive women: a cause of hemolytic disease of the newborn. Am J Obstet Gynecol 1983; 145: 1069-1075.
16. Ostgård P, Fevang F, Komstad L,. Anti-D in a "D-positive" mother giving rise to a severe hemolytic disease of the newborn. A dilemma in antenatal immunohaematological testing. Acta Paediatr Scand 1986; 75: 175-178.
17. Mayne KM, Allen DL, Bowel PJ,. Partial D women with anti-D alloimmunization in pregnancy. Clin Lab Haematol 1991; 13: 239-244.
18. Domen RE, Hoetge GA,. Alloanti-D following transfusion in patients with the weak D (Du) phenotype [abstract]. Blood 1997; 90 (Suppl 1, Pt 2): 130b.
19. u der Mutter. Zentralbl Gynakol 1970; 6: 176-178.
20. Lacey PA, Caskey CR, Werner DJ, et-al. Fatal hemolytic disease of the newborn due to anti-D in an Rh-positive DU variant mother. Transfusion 1983; 23: 91-94.
21. Simmons RT, Krieger VI,. Anti-Rh (D) antibodies produced by isoimmunization in an Rh positive woman of the unusual genotype (CDue/CdE). Med J Aust 1960; 2: 1021-1022.
22. Hill Z, Vacl J, Kalasová E, et-al. Haemolytic disease of the newborn due to anti-D antibodies in a Du positive mother. Vox Sang 1974; 27: 92-94.
23. Zaino EC, Applewhaite F,. Antibodies to part of the Rh0 antigen complex occurring in two women with Rh0 variants. Transfusion 1975; 15: 256-259.
24. Kimball MG, Andrews L, Konugres AA,. Hemolytic disease of the newborn caused by anti-D in a Du positive woman [abstract]. Proc Mass Assoc Blood Banks Ninth Annu Spring Semin 1981; 109.
25. Stedman CM, White CA,. Fatal hydrops fetalis caused by anti-D in a mother with partial D. Obstet Gynecol 2004; 104: 194-195.
26. Cannon M, Pierce R, Taber EB, et-al. Fatal hydrops fetalis caused by anti-D in a mother with partial D. Obstet Gynecol 2003; 102: 1143-1145.
27. Kahwash E, Leonard J, Lockwood W,. A 60-year-old Rh(D)-positive women with anti-D in her serum. Lab Med 2004; 35: 413-414.
28. Prasad MR, Krugh D, Rossi KQ, et-al. Anti-D in Rh positive pregnancies. Am J Obstet Gynecol 2006; 195: 1158-1162.
29. Yazer MH, Triulzi DJ,. Detection of anti-D in D+ recipients transfused with D+ red blood cells. Transfusion 2007; 47: 2197-2201.
30. Flegel WA, Gassner C, Müller TH, et-al. The molecular basis of weak D. Vox Sang 1998; 74 (Suppl 1): 55.
31. Wagner FF, Gassner C, Müller TH, et-al. Molecular basis of weak D phenotypes. Blood 1999; 93: 385-393.
32. Hemker MB, Ligthart PC, Berger L, et-al. DAR, a new RhD variant involving exons 4, 5, and 7, often in linkage with ceAR, a new Rhce variant frequently found in African blacks. Blood 1999; 94: 4337-4342.
33. Wagner FF, Frohmajer A, Ladewig B, et-al. Weak D alleles express distinct phenotypes. Blood 2000; 95: 2699-2708.
34. Flegel WA, Khull S, Wagner FF,. Primary anti-D immunization by weak D type 2 RBC. Transfusion 2000; 40: 428-434.
35. Avent ND, Liu W, Scott ML, et-al. Site directed mutagenesis of the human Rh D antigen: molecular basis of D epitopes. Vox Sang 2000; 78 (Suppl 2): 83-89.
36. Müller TH, Wagner FF, Trockenbacher A, et-al. PCR screening for common weak D types shows different distributions in three Central European populations. Transfusion 2001; 41: 45-52.
37. Wagner FF, Ernst M, Sonneborn HH, et-al. A D(V)-like phenotype is obliterated by A226P in the partial D DBS. Transfusion 2001; 41: 1052-1058.
38. Wagner FF, Frohmajer A, Flegel WA,. RHD positive haplotypes in D negative Europeans. BMC Genet 2001; 2: 10.
39. Legler TJ, Maas JH, Köhler M, et-al. RHD sequencing: a new tool for decision making on transfusion therapy and provision of Rh prophylaxis. Transfus Med 2001; 11: 383-388.
40. Wagner FF, Eicher NI, Jorgensen JR, et-al. DNB: a partial D with anti-D frequent in Central Europe. Blood 2002; 100: 2253-2256.
41. Shao CP, Maas JH, Su YQ, et-al. Molecular background of Rh D-positive, D-negative, D(el) and weak D phenotypes in Chinese. Vox Sang 2002; 83: 156-161.
42. Flegel WA, Curin-Serbec V, Delamaire M, et-al. Section 1B: Rh flow cytometry. Coordinator's report. Rhesus index and antigen density: an analysis of the reproducibility of flow cytometric determination. Transfus Clin Biol 2002; 9: 33-44.
43. Wagner FF, Ladewig B, Flegel WA,. The RHCE allele ceRT: D epitope 6 expression does not require d-specific amino acids. Transfusion 2003; 43: 1248-1254.
44. Wagner FF, Moulds JM, Tounkara A, et-al. RHD allele distribution in Africans of Mali. BMC Genet 2003; 4: 14.
45. Ansart-Pirenne H, Asso-Bonnet PY, Le Pennec M, et-al. RhD variants in whites; consequences for checking clinically relevant alleles. Transfusion 2004; 44: 1282-1286.
46. Denomme GA, Wagner FF, Fernandez BJ, et-al. Partial, weak D types, and novel RHD alleles among 33, 864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005; 45: 1554-1560.
47. Wagner FF, Moulds JM, Flegel WA,. Genetic mechanisms of Rhesus box variation. Transfusion 2005; 45: 338-344.
48. Wagner T, Körmöczi GF, Buchta C, et-al. Anti-D immunization by DEL red blood cells. Transfusion 2005; 45: 520-526.
49. Chen Q, Flegel WA,. Random survey for RHD alleles among D+ European persons. Transfusion 2005; 45: 1183-1191.
50. Yasuda H, Ohto H, Ishikawa Y,. Secondary anti-D immunization by Del red blood cells. Transfusion 2005; 45: 1581-1584.
51. Doescher A, Flegel WA, Petershofen EK, et-al. Weak D type 1.1 exemplifies another complexity in weak D genotyping. Transfusion 2005; 45: 1568-1573.
52. Esteban R, Montero R, Flegel WA, et-al. The D category VI type 4 allele is prevalent in the Spanish population. Transfusion 2006; 46: 616-623.
53. Flegel WA, Wagner FF, Chen Q, et-al. The RHCE allele ceCF: the molecular basis of Crawford (RH43). Transfusion 2006; 46: 1334-1342.
54. Lüttringhaus TA, Cho D, Ryang DW, et-al. An easy RHD genotyping strategy for D- East Asian persons applied to Korean blood donors. Transfusion 2006; 46: 2128-2137.
55. Flegel WA,. How I manage donors and patients with a weak D phenotype. Curr Opin Hematol 2006; 13: 476-483.
56. Yu X, Wagner FF, Witter B, et-al. Outliers in RhD membrane integration are explained by variant RH haplotypes. Transfusion 2006; 46: 1343-1351.
57. Avent ND, Martinez A, Flegel WA, et-al. The BloodGen project: toward mass scale comprehensive genotyping of blood donors in the European Union and beyond. Transfusion 2007; 47 (Suppl 1): 40S-46.
58. Flegel WA,. Blood group genotyping in Germany. Transfusion 2007; 47 (Suppl 1): 47S-53S.
59. Yan L, Wu J, Zhu F, et-al. Molecular basis of D variants in Chinese persons. Transfusion 2007; 47: 471-477.
60. Le Maréchal C, Guerry C, Benech C, et-al. Identification of 12 novel RHD alleles in western France by denaturing high-performance liquid chromatography analysis. Transfusion 2007; 47: 858-863.
61. Polin H, Danzer M, Hofer K, et-al. Effective molecular RHD typing strategy for blood donations. Transfusion 2007; 47: 1350-1355.
62. Flegel WA, von Zabern I, Doescher A, et-al. DCS-1, DCS-2 and DFV share amino acid substitutions at the extracellular RhD protein vestibule. Transfusion 2008; 4: 25-33.
63. Christiansen M, Samuelsen B, Christiansen L, et-al. Correlation between serology and genetics of weak D types in Denmark. Transfusion 2008; 48: 187-193.
64. Flegel WA, von Zabern I, Wagner FF,. Six years' experience performing RHD genotyping to confirm D- red blood cell units in Germany for preventing anti-D immunization. Transfusion 2009; 49: 465-471.
65. Touinssi M, Chapel-Fernandes S, Granier T, et-al. Molecular analysis of inactive and active RHD alleles in native Congolese cohorts. Transfusion 2009; 49: 1353-1360.
66. Flegel WA, von Zabern I, Doescher A, et-al. D variants at the RhD vestibule in the weak D type 4 and Eurasian D clusters. Transfusion 2009; 49: 1059-1069.
67. Bugert P, Scharberg EA, Geisen C, et-al. RhCE protein variants in Southwestern Germany detected by serological routine testing. Transfusion 2009; 49: 1793-1802.
68. Avent ND, Martinez A, Flegel WA, et-al. The Bloodgen Project of the European Union, 2003-2009. Transfus Med Hemother 2009; 36: 162-167.
69. Wang D, Lane C, Quillen K,. Prevalence of RHD variants, confirmed by molecular genotyping, in a multiethnic prenatal population. Am J Clin Pathol 2010; 134: 438-442.
70. Schmid P, von Zabern I, Scharberg EA, et-al. Specific amino acid substitutions cause distinct expression of JAL (RH48) and JAHK (RH53) antigens in RhCE and not in RhD. Transfusion 2010; 50: 267-269.
71. McGann H, Wenk RE,. Alloimmunization to the D antigen by a patient with weak D type 21. Immunohematology 2010; 26: 27-29.
72. Shao CP,. Transfusion of RhD-positive blood in "Asian type" DEL recipients. N Engl J Med 2010; 362: 472-473.
73. Krog GR, Clausen FB, Berkowicz Jørgensen L, et-al. Is current serologic RhD typing of blood donors sufficient for avoiding immunization of recipients? Transfusion 2011; 51: 2278-2285.
74. Szczepura S, Osipenko L, Freeman K,. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011; 11: 5.
75. Pham BN, Roussel M, Peyrard T, et-al. Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies? Transfusion 2011; 51: 2679-2685.
76. Chen Q, Li M, Li M, et-al. Molecular basis of weak D and DEL in Han population in Anhui Province, China. Chin Med J (Engl) 2012; 125: 3251-3255.
77. Brajovich ME, Boggione CT, Biondi CS, et-al. Comprehensive analysis of RHD alleles in Argentineans with variant D phenotypes. Transfusion 2012; 52: 389-396.
78. Fichou Y, Chen JM, Le Maréchal C, et-al. Weak D caused by a founder deletion in the RHD gene. Transfusion 2012; 52: 2348-2355.
79. Srijinda S, Suwanasophon C, Visawapoka U, et-al. RhC[sic] phenotyping, adsorption/elution test, and SSP-PCR: the combined test for D-eluate phenotype screening in Thai RhD-negative blood donors. ISRN Hematol 2012; 2012: 358316.
80. Cruz BR, Chiba AK, Moritz E, et-al. RHD alleles in Brazilian blood donors with weak D or D-negative phenotypes. Transfus Med 2012; 22: 84-89.
81. Moussa H, Tsochandaridis M, Chakroun T, et-al. Molecular background of D-negative phenotype in the Tunisian population. Transfus Med 2012; 22: 192-198.
82. Kacem N, Chakroun T, Moussa H, et-al. RHD zygosity assignments based on most probable genotype and hybrid Rhesus box detection in Tunisia. Transfus Med 2012; 22: 362-366.
83. Hussein E, Teruya J,. Weak D types in the Egyptian population. Am J Clin Pathol 2013; 139: 806-811.
84. Martin FO, de Menezes SS, Chiba AK, et-al. RHD gene polymorphisms in alloimmunized RhD-negative individuals with high rate of racial admixture. Transfus Apher Sci 2013; 48: 113-116.
85. Fichou Y, Le Maréchal C, Jamet D, et-al. Establishment of a medium-throughput approach for the genotyping of RHD variants and report of nine novel rare alleles. Transfusion 2013; 53: 1821-1828.
86. Pham BN, Roussel M, Gien D, et-al. Molecular analysis of patients with weak D and serologic analysis of those with anti-D (excluding type 1 and type 2). Immunohematology 2013; 29: 55-62.
87. Orzińska A, Guz K, Polin H, et-al. RHD variants in Polish blood donors routinely typed as D-. Transfusion 2013; 53 (Suppl 2): 2945-2953.
88. Abdelrazik AM, Elshafie SM, Ezzat Ahmed GM, et-al. Combining serology and molecular typing of weak D role in improving D typing strategy in Egypt. Transfusion 2013; 53 (Suppl 2): 2940-2944.
89. Chou ST, Jackson T, Vege S, et-al. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013; 122: 1062-1071.
90. Reid ME, Halter Hipsky C, Hue-Roye K, et-al. Genomic analysis of RH alleles to improve transfusion therapy in patients with sickle cell disease. Blood Cells Mol Dis 2014; 52: 195-202.
91. Ouchari M, Chakroun T, Abdelkefi S, et-al. Anti-D- auto-immunization in a patient with weak D type 4.0. Transfus Clin Biol 2014; 12: 43-46.
92. Gu J, Wang DX, Shao CP, et-al. Molecular basis of DEL phenotype in the Chinese population. BMC Med Genet 2014; 15: 54.
93. Flegel WA, Wagner FF, Müller TH, et-al. Rh phenotype prediction by DNA typing and its application to practice. Transfus Med 1998; 8: 281-302.
94. Flegel WA, Wagner FF,. Molecular genetics of RH. Vox Sang 2000; 78 (Suppl 2): 109-115.
95. Flegel WA, Wagner FF,. Molekularbiologie von partial D und weak D: Bedeutung für die Arbeit in der Blutzentrale. MTA Dialog 2002; 8: 662-665.
96. Avent ND, Reid M,. The Rh blood group system: a review. Blood 2000; 15: 375-387.
97. Flegel WA, Wagner FF,. Molecular biology of partial D and weak D: implications for blood bank practice. Clin Lab 2002; 48: 53-59.
98. Westhoff CM,. The Rh blood group system in review: a new face for the next decade. Transfusion 2004; 44: 1663-1673.
99. Pisacka M, Vytiskova J, Zavadil J, et-al. Slabé a variantní RhD antigeny-charakteristiky a frekvence typu, vyšetrovaných v letech 1997-2002 v Referencní laboratori pro imunohematologii. Transfuze A Hematologie Dnes 2004; 9: 37-47.
100. Wagner FF, Flegel WA,. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology 2004; 20: 23-36.
101. Flegel WA,. Homing in on D antigen immunogenicity. Transfusion 2005; 45: 466-468.
102. Garratty G,. Do we need to be more concerned about weak D antigens? Transfusion 2005; 45: 1547-1551.
103. Westhoff CM,. Review: the Rh blood group D antigen... dominant, diverse, difficult. Immunohematology 2005; 21: 155-163.
104. Flegel WA,. Molecular genetics of RH and its clinical application. Transfus Clin Biol 2006; 13: 4-12.
105. Engelfriet CP, Reesink HW,. Testing for weak D. Vox Sang 2006; 90: 140-153.
106. Noizat-Pirenne F, Verdier M, Lejealle A, et-al. Weak D phenotypes and transfusion safety: where do we stand in daily practice? Transfusion 2007; 47: 1616-1620.
107. Westhoff CM,. The structure and function of the Rh antigen complex. Semin Hematol 2007; 44: 42-50.
108. Westhoff CM,. Rh complexities: serology and DNA genotyping. Transfusion 2007; 47: 17S-22S.
109. Flegel WA, Denomme GA, Yazer MH,. On the complexity of D antigen typing: a handy decision tree in the age of molecular blood group diagnostics. J Obstet Gynaecol Can 2007; 29: 746-752.
110. Westhoff CM,. Molecular genotyping for RHD: what (not) to do? Transfusion 2007; 47: 1337-1339.
111. Flegel WA,. The genetics of the Rhesus blood group system. Dtsch Arztebl 2007; 104: A651-657.
112. Flegel WA, Wagner FF,. Genotyping of red blood cell, granulocyte and platelet antigens: current applications in the German-speaking countries. In:, Scharf RE, editor. Progress and challenges in transfusion medicine, hemostasis and hemotherapy. Freiburg: Karger; 2008. p. 189-198.
113. Westhoff CM,. The potential of blood group genotyping for transfusion medicine practice. Immunohematology 2008; 24: 190-195.
114. Denomme GA, Dake LR, Vilensky D, et-al. Rh discrepancies caused by variable reactivity of partial and weak D types with different serologic techniques. Transfusion 2008; 48: 473-478.
115. Denomme GA, Flegel WA,. Applying molecular immunohematology discoveries to standards of practice in blood banks: now is the time. Transfusion 2008; 48: 2461-2475.
116. Flegel WA,. Molecular genetics and clinical applications for RH. Transfus Apher Sci 2011; 44: 81-89.
117. Sandler SG, Li W, Langeberg A, et-al. New laboratory procedures and Rh blood type changes in a pregnant woman. Obstet Gynecol 2012; 119: 426-428.
118. Wagner FF,. RHD PCR of D-negative blood donors. Transfus Med Hemather 2013; 40: 172-181.
119. Daniels G,. Variants of RhD-current testing and clinical consequences. Br J Haematol 2013; 161: 461-467.
120. Flegel WA, Roseff S, Tholpady A,. Phasing-in RHD genotyping. Arch Pathol Lab Med 2014; 138: 585-588.
121. Wagner FF, Ladewig B, Angert KS, et-al. The DAU allele cluster of the RHD gene. Blood 2002; 100: 306-311.
122. Flegel WA,. Are weak D RBCs really immunogenic? Transfusion 2006; 46: 1063-1064.
123. Wolinsky H,. A mythical beast: increased attention highlights the hidden wonders of chimeras. EMBO Rep 2007; 8: 212-214.
124. Flegel WA,. Will MICA glitter for recipients of kidney transplants? N Engl J Med 2007; 357: 1337-1339.
125. Quill E,. Blood-matching goes genetic. Science 2008; 319: 1478-1479.
126. Ramsey G,. Q&A: giving Rh immune globulin to obstetrical patients with weak-D phenotypes. AABB News 2011; 6-7.
127. Flegel WA, Denomme GA,. Allo- and autoanti-D in weak D types and in partial D. Transfusion 2012; 52: 2067-2069.
128. von Zabern I, Wagner FF, Moulds JM, et-al. D category IV: a group of clinically relevant and phylogenetically diverse partial D. Transfusion 2013; 53 (Suppl 2): 2960-2973.
129. Willard H, Ginsburg GS,. Genomic and personalized medicine. 1st ed. Philadelphia (PA): Elsevier; 2009.
130. Konugres AA, Polesky HF, Walker RH,. Rh immune globulin and the Rh-positive, Du variant mother. Transfusion 1982; 22: 76-77.
131. Lowe AD, Green SM, Voak D, et-al. A human-human monoclonal anti-D by direct fusion with a lymphoblastoid line. Vox Sang 1986; 51: 212-216.
132. Jones J, Scott ML, Voak D,. Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors. Transfus Med 1995; 5: 171-184.
133. Jones J, Filbey D,. Selection of monoclonal antibodies for the identification of D variants: ability to detect weak D and to split epD2, epD5 and epD6/7. Vox Sang 1996; 70: 173-179.
134. Scott ML, Voak D, Jones JW, et-al. A structural model for 30 Rh D epitopes based on serological and DNA sequence data from partial D phenotypes. Transfus Clin Biol 1996; 3: 391-396.
135. Garratty G, Glynn SA,. McEntire for the Retrovirology Epidemiology Donor Study. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004; 44: 703-706.
136. Jenkins CM, Johnson ST, Bellissimo DB, et-al. Incidence of weak D in blood donors typed as D positive by the Olympus PK 7200. Immunohematology 2005; 21: 152-154.
137. Judd WD, Moulds M, Schlanser G,. Reactivity of FDA-approved anti-D reagents with partial D red blood cells. Immunohematology 2005; 21: 146-148.
138. Whitaker BI, Hinkins S,. The 2011 national blood collection and utilization survey report. US Department of Health and Human Services, Rockville, Maryland [cited 2014 Nov 20]. Available from: http://www.hhs.gov/ash/bloodsafety/2011-nbcus.pdf.
139. Hawk AF, Chang EY, Shields SM, et-al. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013; 122: 579-585.
140. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. Births: preliminary data for 2012. National Vital Statistics Reports 2013;62(3).
141. Flegel WA, Chiosea I, Sachs UJ, et-al. External quality assessment in molecular immunohematology: the INSTAND proficiency test program. Transfusion 2013; 53 (Suppl 2): 2850-2858.
142. Kim KH, Kim KE, Woo KS, et-al. Primary anti-D immunization by DEL red blood cells. Korean J Lab Med 2009; 29: 361-365.
143. Scientific Committee of the Joint Blood Council, Standards Committee of the American Association of Blood Banks. Standards for a blood transfusion service. 1st ed. Washington, DC: Joint Blood Council; 1958.
144. Oberman HA, editor. Standards for blood banks and transfusion services. 10th ed. Washington, DC: American Association of Blood Banks; 1981.
145. American College of Obstetricians and Gynecologists. The selective use of Rho (D) immune globulin (RhIG). Technical Bulletin #61, 1981.
146. American College of Obstetricians and Gynecologists. Prevention of Rh D alloimmunization/number 4, May1999 (Replaces Educational Bulletin Number 147, October 1990). Int J Gynecol Obstet 1999; 66: 63-70.
147. Fridey J, editor. Standards for blood banks and transfusion services. 22th ed. Bethesda (MD): American Association of Blood Banks; 2003.
148. Fung MK, Grossman BJ, Hillyer CD, et-al., editors. Technical manual. 18th ed. Bethesda (MD): American Association of Blood Banks; 2014.
149. Levitt J, editor. Standards for blood banks and transfusion services. 29th ed. Bethesda (MD): American Association of Blood Banks; 2014.